At the same time, it was found that adding duvelisib to the culture of CAR-T cells could decrease the expression of PD-1, LAG-3, and TIM-3 in CD4+ and CD8+ subsets, increasing the survival rate of mice by enhancing CAR-T cells’ expansion and their anti-CLL efficacy [70]. Here, CD8A is linked to B-cell chronic lymphocytic leukemia.